Nexstim enters into alliance with Inomed
Translation: Original comment published in Finnish on 5/5/2024 at 10:54 pm EEST.
Nexstim announced on Friday that it has entered into a strategic alliance with Inomed Inc. The aim of the collaboration is to strengthen marketing, sales and application support. It is our understanding that Nexstim's technology has synergies with Inomed's electroencephalogram (EEG) measurement technology. We believe the partnership will contribute to Nexstim's sales and marketing efforts, but the news has no direct impact on our forecasts and view on the stock.
Synergies between TMS stimulation and EEG measurement
Nexstim previously announced that it has developed a module for the NBS System 5 that allows Nexstim's TMS stimulation to be paired with EEG measurement. Our previous comment on this news can be found here. We understand that this is Inomed's EEG measurement technology. The companies now appear to be expanding their cooperation in the US market in terms of sales, marketing and application support. The collaboration should help Nexstim to expand awareness of its technology to new customers. In the longer term, we believe that the technological solutions developed by the companies could provide customers with new solutions that combine TMS stimulation and EEG measurement. At this stage, however, the collaboration is likely to be of limited commercial value.
Nexstim
Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.
Read more on company pageKey Estimate Figures28.04
2023 | 24e | 25e | |
---|---|---|---|
Omsætning | 7,2 | 8,3 | 10,8 |
vækst-% | -23,93 % | 14,85 % | 30,31 % |
EBIT (adj.) | -1,2 | -0,7 | 0,6 |
EBIT-% (adj.) | -16,94 % | -8,53 % | 5,43 % |
EPS (adj.) | -0,18 | -0,11 | 0,07 |
Udbytte | 0,00 | 0,00 | 0,00 |
Udbytte % | |||
P/E (adj.) | - | - | 43,32 |
EV/EBITDA | - | 225,60 | 18,27 |